SurModics, Inc. (NASDAQ:SRDX) Receives $62.00 Consensus Target Price from Brokerages
SurModics, Inc. (NASDAQ:SRDX) has earned a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $62.00.
A number of equities analysts have recently commented on the stock. Barrington Research set a $64.00 price objective on shares of SurModics and gave the stock a “buy” rating in a report on Thursday, May 2nd. Zacks Investment Research cut shares of SurModics from a “buy” rating to a “hold” rating and set a $41.00 price objective for the company. in a research report on Tuesday, July 23rd. BidaskClub cut shares of SurModics from a “hold” rating to a “sell” rating in a research report on Tuesday. ValuEngine upgraded shares of SurModics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Finally, Lake Street Capital set a $75.00 price objective on shares of SurModics and gave the company a “buy” rating in a research report on Thursday, May 2nd.
SRDX stock traded up $0.44 on Tuesday, hitting $43.84. 30,015 shares of the company’s stock traded hands, compared to its average volume of 111,266. SurModics has a 1-year low of $38.06 and a 1-year high of $82.35. The firm has a market cap of $589.81 million, a PE ratio of 89.47, a price-to-earnings-growth ratio of 10.41 and a beta of 1.18. The stock’s fifty day moving average is $41.47.
In other news, VP Joseph J. Stich sold 2,000 shares of SurModics stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $47.00, for a total transaction of $94,000.00. Following the completion of the sale, the vice president now owns 50,637 shares in the company, valued at approximately $2,379,939. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Gary R. Maharaj sold 5,000 shares of SurModics stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $42.66, for a total transaction of $213,300.00. Following the sale, the chief executive officer now owns 150,235 shares of the company’s stock, valued at approximately $6,409,025.10. The disclosure for this sale can be found here. Insiders sold a total of 17,000 shares of company stock valued at $744,550 in the last 90 days. Corporate insiders own 6.30% of the company’s stock.
Large investors have recently modified their holdings of the company. Trigran Investments Inc. grew its stake in shares of SurModics by 15.1% in the second quarter. Trigran Investments Inc. now owns 927,168 shares of the company’s stock valued at $40,023,000 after acquiring an additional 121,910 shares in the last quarter. Janus Henderson Group PLC increased its position in SurModics by 54.8% during the 1st quarter. Janus Henderson Group PLC now owns 325,885 shares of the company’s stock valued at $14,169,000 after purchasing an additional 115,389 shares during the period. SG Americas Securities LLC increased its position in SurModics by 1,185.2% during the 2nd quarter. SG Americas Securities LLC now owns 65,852 shares of the company’s stock valued at $2,843,000 after purchasing an additional 60,728 shares during the period. American Century Companies Inc. increased its position in SurModics by 92.1% during the 4th quarter. American Century Companies Inc. now owns 104,216 shares of the company’s stock valued at $4,925,000 after purchasing an additional 49,962 shares during the period. Finally, Panagora Asset Management Inc. increased its position in SurModics by 112.9% during the 2nd quarter. Panagora Asset Management Inc. now owns 92,942 shares of the company’s stock valued at $4,012,000 after purchasing an additional 49,290 shares during the period. Institutional investors own 86.45% of the company’s stock.
SurModics Company Profile
Surmodics, Inc, together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment designs, develops, and manufactures interventional medical devices primarily for the peripheral vascular market; and offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.
Recommended Story: Investing strategies using the yield curve
Receive News & Ratings for SurModics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SurModics and related companies with MarketBeat.com's FREE daily email newsletter.